MX2011012229A - Agonistas del receptor de adenosina a3 para la reduccion de la presion intraocular. - Google Patents

Agonistas del receptor de adenosina a3 para la reduccion de la presion intraocular.

Info

Publication number
MX2011012229A
MX2011012229A MX2011012229A MX2011012229A MX2011012229A MX 2011012229 A MX2011012229 A MX 2011012229A MX 2011012229 A MX2011012229 A MX 2011012229A MX 2011012229 A MX2011012229 A MX 2011012229A MX 2011012229 A MX2011012229 A MX 2011012229A
Authority
MX
Mexico
Prior art keywords
reduction
receptor agonists
intraocular pressure
adenosine receptor
subject
Prior art date
Application number
MX2011012229A
Other languages
English (en)
Inventor
Pnina Fishman
Mordechai Farbstein
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of MX2011012229A publication Critical patent/MX2011012229A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente descripción proporciona el uso de un agonista del A3R, como IB-MECA, para reducir en un individuo, preferentemente un ser humano, la presión intraocular (IOP). Igualmente, la invención proporciona una composición farmacéutica y un método para reducir la IOP en un individuo mediante el uso del agonista del A3R.
MX2011012229A 2009-05-17 2010-05-16 Agonistas del receptor de adenosina a3 para la reduccion de la presion intraocular. MX2011012229A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL19878709 2009-05-17
PCT/IL2010/000393 WO2010134067A1 (en) 2009-05-17 2010-05-16 A3 adenosine receptor agonists for the reduction of intraocular pressure

Publications (1)

Publication Number Publication Date
MX2011012229A true MX2011012229A (es) 2011-12-08

Family

ID=42352183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012229A MX2011012229A (es) 2009-05-17 2010-05-16 Agonistas del receptor de adenosina a3 para la reduccion de la presion intraocular.

Country Status (10)

Country Link
US (1) US8557790B2 (es)
EP (1) EP2432475A1 (es)
JP (1) JP5849044B2 (es)
KR (1) KR20120022919A (es)
CN (1) CN102427819A (es)
AU (1) AU2010250759B2 (es)
CA (1) CA2761499A1 (es)
IL (1) IL216114A (es)
MX (1) MX2011012229A (es)
WO (1) WO2010134067A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
AU7331094A (en) 1993-07-13 1995-02-13 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor agonists
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
AU1399297A (en) 1996-01-24 1997-08-20 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
WO1999006053A1 (en) 1997-07-29 1999-02-11 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
US6329349B1 (en) 1997-10-23 2001-12-11 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents
US6217896B1 (en) 1999-04-01 2001-04-17 Uab Research Foundation Conjunctival inserts for topical delivery of medication or lubrication
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
AU2003282359A1 (en) * 2002-11-19 2004-06-15 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
BRPI0517639A (pt) * 2004-11-08 2008-10-14 Can Fite Biopharma Ltd método para o tratamento de ressorção óssea acelerada, composição farmacêutica, e, uso de um agonista de a3ar
CN101083998A (zh) * 2004-11-22 2007-12-05 王者制药研究发展有限公司 用腺苷a3受体激动剂强化治疗hif－1介导的病症
WO2007002139A2 (en) * 2005-06-22 2007-01-04 The Trustees Of The University Of Pennsylvania Neuroprotection of retinal ganglion cells
DK1983990T3 (da) * 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer
BRPI0621052A2 (pt) * 2006-01-27 2012-07-17 Can Fite Biopharma Ltd uso de um agonista de receptor de adenosina a3 (a3ar)
US8153781B2 (en) * 2007-06-29 2012-04-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Dendrimer conjugates of agonists and antagonists of the GPCR superfamily
EP3039030B1 (en) * 2013-08-29 2018-09-19 Yeda Research and Development Co. Ltd. Selective inhibitors of alpha2 isoform of na,k-atpase and use for reduction of intra-ocular pressure

Also Published As

Publication number Publication date
US8557790B2 (en) 2013-10-15
EP2432475A1 (en) 2012-03-28
IL216114A (en) 2015-07-30
KR20120022919A (ko) 2012-03-12
AU2010250759B2 (en) 2013-03-14
CA2761499A1 (en) 2010-11-25
JP2012526798A (ja) 2012-11-01
JP5849044B2 (ja) 2016-01-27
AU2010250759A1 (en) 2011-12-08
CN102427819A (zh) 2012-04-25
WO2010134067A1 (en) 2010-11-25
IL216114A0 (en) 2012-01-31
US20120065155A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
IN2012DN02177A (es)
IN2012DN02702A (es)
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
MY156822A (en) Indole derivatives as s1p1 receptor agonists
WO2010068775A3 (en) Alkyne antagonists of lysophosphatidic acid receptors
WO2010077882A3 (en) Antagonists of lysophosphatidic acid receptors
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
MX363118B (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
JO3078B1 (ar) مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
WO2007150025A3 (en) Purinone derivatives as hm74a agonists
MX2010000724A (es) Metodo para reducir presion intracraneal.
RS20090002A (en) Ep2 agonists
WO2014143754A3 (en) Prostamide-containing intraocular implant
NZ608202A (en) Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
NZ589517A (en) A pharmaceutical composition comprising rebamipide
TW200801022A (en) Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
AU2006342119A8 (en) Soluble human M-CSF receptor and uses thereof
WO2012014083A3 (en) Frataxin mutants
CO6571924A2 (es) Combinaciòn, kit y mètodo para reducir la presión intraocular
CL2012002612A1 (es) Compuestos derivados de benciloxicicloalquiladenosina, como agonistas selectivos de receptores de adenosina a1; composicion farmaceutica oftalmica; y su uso para el tratamiento de una afeccion seleccionada entre presion intraocular elevada, hipertension ocular o glaucoma.
MY160383A (en) Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
GB201014391D0 (en) Drug composition and its use in therapy
MX2012007397A (es) Composiciones y metodos para reducir la presion intraocular.
WO2013170086A3 (en) Formulations for the delivery of active ingredients
MX2011012229A (es) Agonistas del receptor de adenosina a3 para la reduccion de la presion intraocular.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal